No headlines found.
Contineum Therapeutics Announces Appointment of Troy Ignelzi to Board of Directors
Business Wire (Mon, 20-May 4:05 PM ET)
Contineum Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
Business Wire (Thu, 16-May 4:05 PM ET)
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.
Contineum Therapeutics trades on the NASDAQ stock market under the symbol CTNM.
As of May 29, 2024, CTNM stock price climbed to $15.35 with 15,122 million shares trading.
CTNM has a market cap of $394.85 million. This is considered a Small Cap stock.
The top ETF exchange traded funds that CTNM belongs to (by Net Assets): VTI, VXF, VTWO, VTWG, VTWV.
CTNM support price is $14.05 and resistance is $15.35 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CTNM stock will trade within this expected range on the day.